Published in The Lancet, final overall survival results of the phase 3 TALAPRO-2 trial show that talazoparib plus enzalutamide significantly…
Prostate Cancer Group
The phase 3, multi-center, open-label, randomized CONTACT-02 trial, directed by Neeraj Agarwal of the Huntsman Cancer Institute at the University…
Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide…
Published in Cell Reports Medicine*, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation…
